FONT-SIZE Plus   Neg

BTG Reports Positive Results From Second US Pivotal Phase III Trial Of Varisolve

BTG Plc (BGC.L) announced the successful outcome of VANISH-1, the second and final US pivotal Phase III trial of Varisolve (polidocanol endovenous microfoam (PEM)) as a potential treatment for patients with saphenofemoral junction incompetence and symptomatic and/or visible varicose veins. All end points were met with all active PEM concentrations with a high degree of statistical significance, the company said.

Patients treated with PEM showed a statistically significant improvement in symptoms, the primary endpoint, versus patients who received placebo. The co-secondary endpoints of improvement in appearance in PEM-treated patients compared with patients who received placebo, as measured by both a patient-reported outcome and by a blinded independent panel review of photographs, were also met.

In addition, the three tertiary endpoints, response to treatment as determined by duplex ultrasound, change in the Venous Clinical Severity Score and Quality of Life as measured by the modified VEINES-QOL/Sym questionnaire, were all statistically significantly better for patients treated with PEM compared to patients who received placebo.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Pilot of an American Airline died as he was flying the Airbus A320 from Phoenix to Boston. The co-pilot managed the situation and made an emergency landing at Syracuse Hancock International airport on Monday. The Flight was carrying 147 passengers and five crew members. Popular social media company Twitter Inc. Monday confirmed that co-founder and one of the largest shareholders Jack Dorsey will be permanent chief executive officer. Xbox Live users are aggravated about repeated outages that have prevented gamers from accessing online multiplayer features.
comments powered by Disqus
Follow RTT